Avelumab and Merkel Cell Carcinoma Risk: What Studies Show

From General Health to Occupational Exposure

In the domain of mass production, the legacy theme of general health and science information has long served as a foundation for public understanding of environmental and occupational factors. This broad context historically emphasized lifestyle and community-level influences on well-being, providing a baseline for awareness without delving into specific exposures. As industrial processes have evolved, however, attention has increasingly turned to the materials and compounds encountered in manufacturing environments. The shift from general health discourse to a more focused occupational exposure concern is a natural progression, reflecting the need to examine how specific agents in production settings may interact with biological systems. Within this transition, the concept of exposure to therapeutic agents—such as Avelumab, a monoclonal antibody used in oncology—emerges as a point of inquiry. While Avelumab is primarily administered in clinical settings, its presence in mass production contexts, such as pharmaceutical manufacturing, raises questions about potential risks for workers. The pivot from general health information to occupational exposure thus centers on understanding how sustained contact with such compounds might correlate with health outcomes, including the risk of conditions like Merkel cell carcinoma. This shift underscores the importance of moving from broad health literacy to targeted surveillance in industrial hygiene, without yet invoking specific mechanistic pathways.

Avelumab: Mechanism and Approved Use

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). This makes avelumab the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Merkel Cell Carcinoma: Etiology and Epidemiology

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the human Merkel cell polyomavirus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab and pembrolizumab, offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/).

Evidence on Avelumab Refractoriness and Alternative Treatments

For patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a retrospective study conducted at three academic sites in Germany, clinical and molecular data of five patients with metastatic MCC refractory to avelumab who were later treated with combined ipilimumab and nivolumab were collected and evaluated (https://pubmed.ncbi.nlm.nih.gov/33439294/). Three out of five patients responded to combined ipilimumab and nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported on ipilimumab plus nivolumab in avelumab-refractory MCC, noting that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC further confirmed that despite advances in systemic therapy, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Causation and Risk Context

From a causation perspective, the relationship between avelumab and Merkel cell carcinoma is not one of causation in the sense of the drug causing the disease. Rather, avelumab is a therapeutic agent used to treat MCC. The evidence indicates that avelumab is an approved and effective treatment for metastatic MCC, with a demonstrated response rate in clinical trials. The risk narrative for affected patients centers on the adequacy of warnings regarding avelumab's use and its potential adverse effects. The primary risk associated with avelumab is not that it causes MCC, but that it may be ineffective or lead to immune-related adverse events in a subset of patients. The timeline between exposure to avelumab and documented harm typically involves the development of immune-related adverse events during treatment, or progression of MCC despite therapy. For patients who are refractory to avelumab, alternative treatments such as combined ipilimumab and nivolumab may be considered, as evidenced by the studies showing responses in avelumab-refractory patients (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). In summary, the evidence supports that avelumab is a standard treatment for metastatic MCC, with a well-characterized efficacy and safety profile. The risk for patients involves the possibility of non-response or immune-related adverse events, rather than avelumab causing MCC. Adequate warnings and patient education about these risks are essential components of clinical management.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab does not cause Merkel cell carcinoma. It is a therapeutic agent used to treat metastatic Merkel cell carcinoma. The primary risks associated with avelumab are potential lack of efficacy or immune-related adverse events, not causation of the disease.

What is the evidence for avelumab's effectiveness in Merkel cell carcinoma?

Avelumab was approved based on the phase II JAVELIN Merkel 200 trial, which showed objective responses in about one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is the first drug specifically approved for this indication.

What treatment options exist for patients who do not respond to avelumab?

For patients refractory to avelumab, combined ipilimumab and nivolumab has shown responses in some cases, as reported in retrospective studies (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). However, about 50% of patients may still progress on therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.